medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2014, Número 4

<< Anterior Siguiente >>

Rev Invest Clin 2014; 66 (4)


Vicisitudes de la hepatitis C en México

Kershenobich D, Aguilar-Valenzuela LM, Muñoz L

Idioma: Español
Referencias bibliográficas: 18
Paginas: 299-302
Archivo PDF: 105.01 Kb.


FRAGMENTO

ASPECTOS MÉDICOS
Aproximadamente 150 millones de personas en el mundo están crónicamente infectadas por el virus de la hepatitis C (VHC) y su prevalencia global estimada para 2020 podría aumentar tres veces.1


REFERENCIAS (EN ESTE ARTÍCULO)

  1. World Health Organization. Prevention and Control of Viral Hepatitis Infection: Framework for Global Action. Geneva, Switzerland: World Health Organization; 2012. Disponible en: http://www.who int/csr/disease/hepatitis/ Framework/en/

  2. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012; 380: 2095-128.

  3. Ahn J, Flamm SL. Frontiers in the Treatment of Hepatitis C virus infec tion. Gastroenterol Hepatol (NY) 2014; 10: 90-100.

  4. Lange CM, Jacobson IM, Rice ChM, Zeuzem S. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med 2014; 6: 4-15.

  5. Bartosch B, Cosset FL. Cell entry of hepatitis C virus. Virology 2006; 348: 1-12.

  6. Costly cures. The Economist June 7th, 2014.

  7. Hoofnagle JH, Sherker AH. Therapy for Hepatitis C. The Costs of Success. N Engl J Med 2014; 370: 1552-3.

  8. Hepatitis C Industry Global Sales Forecast to 2019. Disponible en: http:// www.rnmarketresearch. com

  9. Hill A, Cooke G. Hepatitis C can be cured globally, but at what cost. Science 2012; 345: 141-2.

  10. PAHO Blood Transfusion Report 2013.

  11. Kershenobich D, Razavi HA, Sánchez- Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31(Suppl. 2): 18-29.

  12. White EF, Garfein RS, Brouwr KC, Lozada R, Ramos R, Firestone-Cruz M, Perez AG, et al. Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Salud Publica Mex 2007; 49: 165-72.

  13. Romero-Figueroa S, Ceballos-Salgado E, Santillán-Arreygue L, Miranda-García M, Rubio-Lezama M, Garduño- García JJ. Risk factors associated with hepatitis C virus infection in an urban population of the State of Mexico. Arch Virol 2012; 157: 329-32.

  14. Catálogo de enfermedades que cubre el Fondo de Protección contra Gastos Catastróficos del Seguro Popular, 2012.

  15. Saludes V, González V, Planas R, Matas L, Ausina V, Martró E. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol 2014; 7: 3431- 42.

  16. Moon S, Jambertr E, Childs M, Von Schien-Angerer T. A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. Globalization and Health 2011; 7: 39-49.

  17. Esmat G. Hepatitis C in the Eastern Mediterranian Region. Eastern Mediterranean Health Journal 2013; 19: 587-8.

  18. Ministry of Health and Population.2008. Egiptyan national control strategy for viral hepatitis 2008-2012.




2020     |     www.medigraphic.com